PERCUTANEOUS PULMONARY VALVE REPLACEMENT:

Slides:



Advertisements
Similar presentations
Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.
Advertisements

Right Ventricular Outflow Obstruction after Tetralogy of Fallot Repair Stephan Ziegeler, MD,* George J. Reul, MD,† Raymond F. Stainback, MD‡ *Department.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.
Role of Interventional Catheterization in Post-Operative TOF Patients Jennifer Rutledge, MD October 25, 2013.
Valvular Heart Disease. Normal heart valves function to maintain the direction of blood flow through the atria and ventricles to the rest of the body.
Current Status and Prospect of Interventional Congenital Heart Disease
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Trans-catheter Aortic Valve Replacement: a UK update. Dr Martyn Thomas Guys and St Thomas’ Hospital.
Transhepatic venous cardiac catheterization
Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,
PRESERVATION OF THE PULMONARY VALVE (NOT JUST THE ANNULUS)
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
Pulmonary Atresia with Intact Ventricular Septum Ali Sepahdari, MD University of Illinois at Chicago.
Pediatric Interventions Cardiac Catheterization and Valvuloplasty.
Vanessa Beretta & Dan Fleming. About CHD A congenital heart defect also known as CHD is a defect in the structure of the heart and great vessels. Most.
Cardiothoracic Surgery. Topics Valvotomy and valve replacement Open heart surgery and cardiac bypass surgery Correction of congenital heart diseases Heart.
Valve Surgery V.Rohn. Valve Surgery History before the era of ECC 1925 – Suttar – first successful digital commisurolysis of mitral valve 1952 – Hufnagel.
Mechanical PVR Pearls & Pitfalls Joseph A. Dearani, MD Division of Cardiovascular Surgery AATS Seattle April 2015.
Adult Cardiac Valve Disease Marvin D. Peyton, M.D. Thoracic and Cardiovascular Surgery University of Oklahoma Health Sciences Center.
Aortic Root Dilatation S/P Ross Procedure
Chapter 9 Heart. Review of Structure and Function The heart is divided into the systemic (left) and pulmonary (right) systems –The pulmonary system has.
Intervention of Aortic Coarctation: from Angioplasty to Stent
3/98medslides.com1 Aortic Valve Homografts A Cinical Perspective Michael E. Staab, MD Rick A. Nishimura, MD Joseph A. Dearani, MD Thomas A. Orszulak, MD.
Ross Operation Seoul National University Hospital Department of Thoracic & Cardiovascular Surgery.
Adult with operated congenital heart disease: what should we check for? January 15 th, h-17h30.
Yoav Dori, MD PhD The Children’s Hospital of Philadelphia
EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.
Affordable Heart Surgery Available in India. Different Heart Surgeries  Angiography  Angioplasty with one medicated stent  Coronary Angioplasty (Including.
| rejuveindiameditour.com.
Cardiovascular system
Quick Reference Guides
Issues and Current Situations in the Development of Endovascular Treatment Devices for Pediatric Cardiology in the US – US Industry Dan Gutfinger, MD,
Reconstruction of pulmonary pathway in congenital cardiac anomalies
Percutaneous valve devices
Division of Cardiovascular Devices
Cardiothoracic Surgery
University of Pennsylvania Philadelphia
Heart - Pathophysiology
Design & Product Development Larry L Wood
Direct Flow Medical Experience with a Conformable, Repositionable, Retrievable, Percutaneous Aortic Valve Reginald Low MD University of California,Davis.
Hans R. Figulla MD,PhD University Heart Center, Jena, Germany
Special Hospital for surgical diseases “Filip Vtori”, Skopje
Adherence to the Labeling
Review of the Latest OUS Data from the Self-Expanding Valve Studies
MedStar Washington Hospital Center Cardiac Catheterization Conference
Congenital Heart Disease
Insights from the Melody Pulmonic Transcatheter Valve Panel
Pediatric cardiac catheterization Part 1 - balloon procedures David Shim, MD The Heart Center Children’s Hospital Medical Center Cincinnati, Ohio.
Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.
Transcatheter Pulmonary Valve Replacement for Right Ventricular Outflow Tract Conduit Dysfunction After the Ross Procedure  Matthew J. Gillespie, MD,
Cardiac Manifestation of DiGeorge Syndrome
One-stop Hybrid Cardiac Surgery
UNCERTAINTY OF RISK: THE CASE OF THE TRICUSPID DEVICES
Adult Congenital Heart Disease Overview of the Population at Risk
Cardiovacular Research Technologies
Update in Cardiac and Thoracic Surgery
George M. Alfieris, MD, Michael F. Swartz, PhD 
Transcatheter Pulmonary Valve Replacement for Right Ventricular Outflow Tract Conduit Dysfunction After the Ross Procedure  Matthew J. Gillespie, MD,
Michael J. Davidson, MD, Frederick G. P. Welt, MD, Andrew C
Percutaneous Pulmonary Valve Replacement: 3-Month Evaluation of Self-Expanding Valved Stents  Tim Attmann, MD, René Quaden, MD, Thomas Jahnke, MD, PhD,
Management of High-Risk Patients With Aortic Stenosis and Coronary Artery Disease  Daniel Wendt, MD, Philipp Kahlert, MD, Tim Lenze, Markus Neuhäuser,
Complex Pediatric Lung Transplantation
Transcatheter aortic valve implantation combined with conventional heart surgery: Hybrid approach for complex cardiac pathologic features  Miralem Pasic,
Pulmonary atresia with VSD Presenter: 吳承諭 Supervisor: 王玠能醫師
Comparison of porcine xenografts and homografts for pulmonary valve replacement in children  Sven Dittrich, MD, Vladimir V Alexi-Meskishvili, MD, PhD,
Transcatheter pulmonary valve replacement using the melody valve for treatment of dysfunctional surgical bioprostheses: A multicenter study  Allison K.
The Rastelli Procedure for Transposition of the Great Arteries: Resection of the Infundibular Septum Diminishes Recurrent Left Ventricular Outflow Tract.
Intersurgeon variability in long-term outcomes after transatrial repair of tetralogy of Fallot: 25 years' experience with 675 patients  Yves d'Udekem,
Presentation transcript:

PERCUTANEOUS PULMONARY VALVE REPLACEMENT: A NEW PARADIGM Michael C. Slack, M.D.

RELEVANT DISCLOSURES Michael C. Slack, M.D. ● AGA Medical/St. Jude Medical Corporation: Teaching Proctor and Consultant (compensated) ● Siemens AX Division, Forchheim, Germany Pediatric Cardiac Catheterization Laboratories Advisory Board Member (uncompensated)

A Pulmonary Valve is contained within the surgical CONDUIT used to treat many forms of structural congenital heart disease…

What are RV to PA CONDUITS? ● Conduits are placed surgically between the right ventricle and the branch pulmonary arteries when no main pulmonary trunk is present or when an alternative path to the pulmonary arteries is required during a complex surgical repair. ● Major types of valved surgical conduits: - human cadaver homografts (pulmonary & aortic) - synthetic material with xenograft valve

Who are the patients that need a CONDUIT that contains a pulmonary valve as part the surgical palliation of their CHD? Structural Congenital Heart Defects that require a CONDUIT as part of the repair: ● Pulmonary Atresia ● Tetralogy of Fallot (coronary issues; absent pulmonary valve) ● Truncus Arteriosus ● Double Outlet Right Ventricle (“Rastelli” Repair) ● Transpostion of the Great Arteries (some) Other defects: ● Ross Procedure (pulmonary autograft) for AS/AI ● other (endocarditis; early conduit dysfunction, etc.)

All Right Ventricle to Pulmonary Artery CONDUITS Eventually Becomes DYSFUNCTIONAL: Histo-pathologic degrading process occurs & depends on type of conduit: ● pulmonary homografts  valve dissolution ● aortic Homografts  calcification & valve stenosis ● xenograft conduits combination of valve hardening and internal “rind” formation reducing the lumen diameter of conduit ● variable timeline: 6 mo (early failure) to 8-10 yrs

Conduit Dysfunction ● RVOT conduit dysfunction results in abnormal RV function & deterioration: RVOT obstruction (RV pressure load) Pulmonary regurgitation (RV volume load) RV Pressure Overload RV Volume Overload

Management of Conduit Dysfunction Traditional Rx Options: Conduit Valve Insufficiency Conduit Valve Stenosis Transcatheter Balloon angioplasty Bare metal stent Surgical conduit replacement: ● Valved conduits Homografts Xenografts ● Bioprostheses (Xenograft leaflet tissue)

Surgical Homograft Performance Freedom from Reoperation Freedom from Failure: Regurgitation Progression > 2 grades Freedom from Failure Freedom from Failure: Stenosis PSG ≥ 50 mmHg Baskett et al. J Thorac Cardiovasc Surgery 2003;126:232-9

TREATMENT OF CONDUIT VALVE DYSFUNCTION PRE 2010 ALL Required Repeat Open-Heart Surgery: POST- JAN 29, 2010 1st Percutaneous Pulmonary Valve System Approved in U.S.

FIRST GENERATION PERCUTANEOUS PULMONARY VALVE CE Mark, Health Canada Approval (2006) 1st US Implant (2007) 1st Implant Paris, France (2000) Bonhoeffer Cohort (ous) (2003-05) 2000 2002 2004 2006 2008 2010 U.S. FDA Approval (HDE) US Cohort (2007-08) Revised TPV (2003) World Wide: >950 patients among >75 centers

FIRST GENERATION PERCUTANEOUS PULMONARY VALVE Bovine jugular venous valve segment Platinum-Iridium Balloon Expandable stent

1st Gen. Pulmonary Valve Indications TPV is indicated for use ONLY in the following conditions: Existence of a full (circumferential) RVOT conduit that was > 16 mm in diameter when originally surgically placed and either Regurgitant RVOT conduits with a clinical indication for invasive or surgical intervention; or Stenotic RVOT conduits where the risk of worsening regurgitation is a relative contraindication to balloon dilatation or stenting

1st Generation Percutaneous Pulmonary Valve: Implant System Components Bovine Jugular Vein Valve sewn to a Balloon Expandable Stent Sheathed Valve Delivery System

Delivery System 22 Fr crossing profile Retractable sheath Balloon-in-Balloon (BIB) catheter 3 outer balloon diameters: 18 mm 20 mm 22 mm The Melody is deployed using a delivery system that is based on a balloon-in-balloon catheter with an integrated retractable sheath that has a 22Fr crossing profile There is one size valve, but the delivery system comes in 3 sizes, with outer balloon diameters of 18, 20, and 22mm 22 Fr crossing profile Retractable sheath

Percutaneous P.V. Implant Cartoon

Valve Delivery Valve Deployment

◄- Before Valve After Pulmonary Valve Implant -►

Percutaneous Pulmonary Valve Early Results: Source: U.S. Trial Data (HDE); Sponsor Executive Summary-FDA, July 22, 2009

Percutaneous Pulmonary Valve Early Results: Source: U.S. Trial Data (HDE); Sponsor Executive Summary-FDA, July 22, 2009

Percutaneous Pulmonary Valve Early Results: Source: U.S. Trial Data (HDE); Sponsor Executive Summary-FDA, July 22, 2009

Percutaneous Pulmonary Valve Early Results: Device Related A.E.s

Coronary compression with ST Δ 1st Gen. Percutaneous P.V. Contraindications: Coronary Artery Passage Adjacent to Conduit (compression during balloon test inflation): No compression Coronary compression with ST Δ

1st Gen. Percutaneous P.V. Contraindications (cont’d): Native RVOT without Conduit Target of Future Second Generation Percutaneous Pulmonary Valve Systems

Investigational Use Only COMPASSION: COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV Study began: 5-2008 Conduits: 16-24mm

Thank You!